Exchange: NASDAQ·Updated 04:25 PM EDT
News
all
press releases
CADL Rises As Biotech Eyes First Commercial Product in 2027 — CEO Points To ‘Meaningful Execution’ Toward BLA Submission In Q4
If the FDA approves aglatimagene besadenovec in the treatment of certain patients with prostate cancer, it would mark the company’s first commercial product.
Stocktwits
More News
CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity
Shares of Candel have drawn rising attention as the company advances its experimental immunotherapy, known as CAN-2409 or aglatimagene, toward potential approval in localized prostate cancer.
Stocktwits
CADL Stock Heads For Biggest Monthly Gains Since December 2024 – Retail Says ‘Our SLS Days Are Coming’
Candel Therapeutics announced the initiation of a Phase 3 trial evaluating lead therapy CAN-2409 in advanced non-small cell lung cancer patients.
Stocktwits
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.
Stocktwits
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks
Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data
Candel Therapeutics presented positive phase 3 prostate cancer data showing improved disease-free survival, while analysts maintained bullish expectations on the stock.read more...
Benzinga
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data
The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo.
Stocktwits
CADL Retail Bulls See Buyout Potential As Key Cancer Data Catalyst Approaches
Candel Therapeutics is set to present data on Friday from its Phase 3 clinical trial of Aglatimagene in patients with localized, intermediate- to high-risk prostate cancer
Stocktwits
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow
Candel Therapeutics generated investor buzz ahead of a key prostate cancer data readout, while its first-quarter loss came narrower than consensus estimates.
Stocktwits
Candel Therapeutics (NASDAQ:CADL) Sets New 12-Month High - Here's What Happened
Candel Therapeutics (NASDAQ:CADL) Hits New 52-Week High - What's Next...
MarketBeat

Advertisement|Remove ads.